System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Bradley S Quon is an expert in Pulmonology at St. Paul's Hospital (Canada, Vancouver) (Canada). As of September 2026, ScienceLeadR ranks Bradley S Quon in the top 1% of experts worldwide for Cystic Fibrosis and Pancreatic Diseases. Bradley S Quon has authored 205 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 823 (community average: 125). How the SLR is computed.

LeadR Profile

Bradley S Quon St. Paul's Hospital (Canada, Vancouver) Canada
823 ScienceLeadR Reputation 823

Unlock

Register Login
Network Map

Pulmonology

Subspecialties: Nephrology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

University of British Columbia

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 205

Citations

Citations: 5 559 1st author: 29 Last author: 64 Unique author: 20

Main journals

J Cyst Fibros 51
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 19
Ann Am Thorac Soc 17
Am J Respir Crit Care Med 10
Chest 9

Best Journals

N Engl J Med 2
Am J Respir Crit Care Med 1
Lancet Respir Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Assessing the impact of elexacaftor/tezacaftor/ivacaftor on work productivity and activity impairment in people living with cystic fibrosis in Canada.
PMID 42736062 — fibrosis, cystic fibrosis, work, presenteeism		J Cyst Fibros20260
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.
PMID 41837895 — safety, fibrosis, cystic fibrosis, adolescent, genotype, therapeutics		Ann Am Thorac Soc20260
Impact of Elexacaftor/Tezacaftor/Ivacaftor (ETI) on Airway and Aystemic Inflammation in Cystic Fibrosis: A Systematic Review.
PMID 42397988 — cytokines, fibrosis, neutrophils, biomarkers, cystic fibrosis		Ann Am Thorac Soc20260
Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor on Health-Related Quality of Life in Adults with Cystic Fibrosis: A 12-Month Multicenter Cohort Study.
PMID 42019640 — quality of life, lung, fibrosis, cohort studies, cystic fibrosis, non-responder		Respir Med20260
Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World Study.
PMID 41738096 — cells, fibrosis, critical care, cystic fibrosis, therapeutics		Am J Respir Crit Care Med20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 4
N/A 3

By status:

Completed 6
Recruiting 1

By type:

Interventional 4
Observational 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS